ANKRD17 Inhibitors
ANKRD17 inhibitors encompass a variety of chemical compounds that intricately modulate the cellular signaling pathways, ultimately leading to the downregulation of ANKRD17 activity. Rapamycin, for instance, is a well-known mTOR inhibitor that specifically binds to the mTOR complex, and given that ANKRD17 functions as a positive regulator of mTOR signaling, its activity is diminished as the complex's assembly is disrupted. This disruption affects the cellular processes that ANKRD17 is involved with, particularly those related to mTORC1 complex formation. Similarly, Torin 1, WYE-354, and AZD8055 are potent mTOR inhibitors that function by directly inhibiting the kinase activity of both mTORC1 and mTORC2 complexes. This inhibition is crucial as ANKRD17 is implicated in mTOR signaling; thus, these inhibitors lead to a reduction in ANKRD17's ability to promote the assembly and signaling of these mTOR complexes. KU-0063794, which selectively inhibits mTOR without affecting PI3K, also contributes to the decrease in ANKRD17 activity by impairing the signaling pathways where ANKRD17 is a known participant.
Furthermore, chemicals like LY294002 and PF-04691502 target upstream components of the PI3K/AKT/mTOR pathway, which is crucial for the functional activity of ANKRD17. LY294002, a PI3K inhibitor, indirectly curtails AKT phosphorylation and activation, leading to a consequential decrease in ANKRD17's role in mTOR signaling given the protein's regulatory function. PF-04691502, as a dual PI3K/mTOR inhibitor, exerts a more extensive influence on the pathway by affecting both upstream and downstream components, resulting in a comprehensive reduction of ANKRD17's function in mTORC1 and mTORC2 signaling. The dual inhibitors, NVP-BEZ235 and GSK2126458, similarly exert their inhibitory effects by targeting both PI3K and mTOR kinases, culminating in decreased ANKRD17 activity. These inhibitors, through their specific and targeted actions, ensure the effective inhibition of ANKRD17 by impeding the pathways and complexes that are essential for its functional activity, thereby maintaining a critical balance within the cellular signaling milieu.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively binds to mTOR (mammalian target of rapamycin) and inhibits its activity. Since ANKRD17 has been identified as a positive regulator of mTOR signaling by facilitating the assembly of the mTOR complexes, the inhibition of mTOR by rapamycin would subsequently result in the decreased functional activity of ANKRD17 due to the disruption of the mTORC1 complex formation. | ||||||
Torin 1 | 1222998-36-8 | sc-396760 | 10 mg | $245.00 | 7 | |
Torin 1 is a potent mTOR inhibitor that works by directly inhibiting the kinase activity of mTORC1 and mTORC2. Given that ANKRD17 enhances the mTOR pathway, the inhibition of mTOR by Torin 1 leads to a reduction in ANKRD17's functional role in promoting mTOR complex assembly and signaling. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that indirectly inhibits AKT phosphorylation and activation. AKT is upstream of mTOR in the PI3K/AKT/mTOR pathway, which ANKRD17 is known to influence. By inhibiting PI3K, LY294002 reduces AKT mediated activation of mTORC1, thereby limiting the functional role of ANKRD17 in mTOR signaling. | ||||||
WYE-354 | 1062169-56-5 | sc-364652 sc-364652A | 10 mg 50 mg | $286.00 $1200.00 | ||
WYE-354 is a mTOR inhibitor that acts similarly to Rapamycin and Torin 1 by inhibiting both mTORC1 and mTORC2 complexes. ANKRD17, which is involved in mTOR signaling, will have decreased activity due to this inhibition, as it is unable to promote the assembly of these complexes when mTOR kinase activity is suppressed. | ||||||
Palomid 529 | 914913-88-5 | sc-364563 sc-364563A | 10 mg 50 mg | $300.00 $1000.00 | ||
Palomid 529 (P529) inhibits the downstream components of the AKT/mTOR pathway. This results in decreased activity of mTOR and subsequent downregulation of ANKRD17's function in mTOR signaling, as ANKRD17 is a known regulator of this pathway. | ||||||
BEZ235 | 915019-65-7 | sc-364429 | 50 mg | $211.00 | 8 | |
NVP-BEZ235 is a dual inhibitor of PI3K and mTOR. It inhibits the kinase activity of both PI3K and mTOR, leading to a decrease in ANKRD17's positive regulation of mTORC1 and mTORC2 assembly and function since ANKRD17's activity is closely linked to the integrity of these complexes. | ||||||
AZD8055 | 1009298-09-2 | sc-364424 sc-364424A | 10 mg 50 mg | $163.00 $352.00 | 12 | |
AZD8055 is an ATP-competitive inhibitor of mTOR kinase activity that affects both mTORC1 and mTORC2. This inhibition disrupts the normal functioning of ANKRD17, which is known to regulate mTORC1 signaling, leading to a decrease in its functional activity as the mTOR complexes cannot be properly formed or activated. | ||||||
PP242 | 1092351-67-1 | sc-301606A sc-301606 | 1 mg 5 mg | $57.00 $172.00 | 8 | |
PP242 is an mTOR inhibitor that works by targeting the ATP-binding site of mTOR. This inhibits both mTORC1 and mTORC2, ultimately leading to a reduction in ANKRD17 activity since ANKRD17 promotes the assembly and function of these mTOR complexes. | ||||||
KU 0063794 | 938440-64-3 | sc-361219 | 10 mg | $209.00 | ||
KU-0063794 is a selective inhibitor of mTOR that does not affect PI3K. It impairs mTORC1 and mTORC2 signaling, which are pathways where ANKRD17 is known to be involved. Thus, the inhibition of mTOR by KU-0063794 leads to a decrease in ANKRD17 activity related to mTOR signaling. | ||||||
GSK2126458 | 1086062-66-9 | sc-364503 sc-364503A | 2 mg 10 mg | $265.00 $1050.00 | ||
GSK2126458 is an oral inhibitor targeting both PI3K and mTOR. By inhibiting these kinases, it diminishes the PI3K/AKT/mTOR pathway, leading to a subsequent decrease in ANKRD17's function | ||||||